505709090 10/04/2019

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5755900

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
INTEGRITY BIO, INC.	07/25/2019

RECEIVING PARTY DATA

Name:	HELIXMITH CO., LTD.	
Street Address:	203, SEOUL NATIONAL UNIVERSITY, 1	
Internal Address:	GWANAK-RO, GWANAK-GU	
City:	SEOUL	
State/Country:	KOREA, REPUBLIC OF	
Postal Code:	08826	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16517323

CORRESPONDENCE DATA

Fax Number: (650)938-5200

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6503357908

Email: kwoo@fenwick.com
Correspondent Name: HAYAN YOON

Address Line 1: FENWICK & WEST LLP
Address Line 2: 801 CALIFORNIA STREET

Address Line 4: MOUNTAIN VIEW, CALIFORNIA 94041

ATTORNEY DOCKET NUMBER:	33730-40319/US (014US)	
NAME OF SUBMITTER:	HAYAN YOON, REG NO. 78,318	
SIGNATURE:	/Hayan Yoon/	
DATE SIGNED:	10/04/2019	

Total Attachments: 2

source=40319 US Executed Assignment (Integrity Bio to Helixmith)#page1.tif source=40319 US Executed Assignment (Integrity Bio to Helixmith)#page2.tif

PATENT 505709090 REEL: 050633 FRAME: 0343

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, Integrity Bio, Inc., a California corporation, having a place of business at 820 Calle Plano, Camarillo, CA 93012 ("ASSIGNOR"), has sold, assigned, and transferred and does hereby sell, assign, and transfer to Helixmith Co., Ltd., a corporation of the Republic of Korea, having a place of business at 5th Fl., Building 203, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea ("ASSIGNEE"), for itself and its successors, transferees, and assignees, the following:

- 1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional or non-provisional application filed under 35 U.S.C. § 111, design application filed under 35 U.S.C. § 171, Registered Community Designs, international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"), and any patents issuing thereon ("PATENT RIGHTS"):
 - Application No. 16/517,323, entitled "LYOPHILIZED PHARMACEUTICAL COMPOSITIONS FOR NAKED DNA GENE THERAPY," filed on July 19, 2019, which claims priority from a provisional application, filed on July 19, 2018, now bearing U.S. Application No. 62/700,655;

and:

- 2. The entire worldwide right, title, and interest in and to:
- (a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications that describe the SUBJECT MATTER that have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and reexaminations) that may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to recover damages for infringement of provisional rights.

ASSIGNOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titled and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER of the above-identified patent applications and Letters Patents; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER of the above-identified patent applications and Letters Patents and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. ASSIGNOR further agrees to provide any successor, transferee, assignee, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

33730/40319/FW/10823333-1

PATENT REEL: 050633 FRAME: 0344

Tale:		JARMACEUTICAL COMPOSITION	
	THERAPY		
Filed:	July 19, 2019	Attorney Docket #:	33730-40319/US (014US)
Application #:	16/517,323		

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the ASSIGNOR has made or will make hereafter no assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

ASSIGNOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or other authority for recordation of this document.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Duly Authorized Representative of ASSIGNOR	Date of Signature
<u>Along my</u>	July 25, 2019
[signature]	
Byzong Chang	
Name	
precident	
Title	
Integrity Bio, Inc.	
Duly Authorized Reprotentative of ASSIGNEE	Date of Signature イェーラ、かり
[signature]	
Sunyoung KIM	
Name	
CEO	
Title	
Helixmith Co., Ltd.	

2

RECORDED: 10/04/2019

33730/40319/EW/10823333.1